Mangrove Partners Cel Sci Corp Transaction History
Mangrove Partners
- $890 Million
- Q2 2024
A detailed history of Mangrove Partners transactions in Cel Sci Corp stock. As of the latest transaction made, Mangrove Partners holds 900,000 shares of CVM stock, worth $648,000. This represents 0.8% of its overall portfolio holdings.
Number of Shares
900,000Holding current value
$648,000% of portfolio
0.8%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CVM
# of Institutions
74Shares Held
6.29MCall Options Held
16.6KPut Options Held
148K-
Vanguard Group Inc Valley Forge, PA2.41MShares$1.74 Million0.0% of portfolio
-
Black Rock Inc. New York, NY775KShares$557,7860.0% of portfolio
-
Geode Capital Management, LLC Boston, MA613KShares$441,2590.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ448KShares$322,3240.0% of portfolio
-
State Street Corp Boston, MA194KShares$139,3250.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $31.2M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...